Pair page
Ipamorelin with Kisspeptin
Mechanism-tag overlap and published literature for Ipamorelin and Kisspeptin, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
growth-hormone-secretagogueselective-ghrelin-receptor-agonist
endogenous-hpg-axis-master-regulator
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Ipamorelin and Kisspeptin have published these mechanism-level observations. Not a co-administration recommendation.
The GH axis operates in parallel to the HPG axis. Combining kisspeptin (HPG stimulation) with GH-axis stimulation (ipamorelin + GHRH) addresses both endocrine axes in longevity-focused protocols. Community-level practice; no controlled data.
Quick facts
Ipamorelin
Kisspeptin
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2014 | Ipamorelin | Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. PMID: 2… PMID 25331030 | human trial |
| — | Ipamorelin | ClinicalTrials.gov. Study of IPAMORELIN on the Management of Postoperative Ileus Following Partial Bowel Resection. NCT00672074. | human trial |
| 2008 | Ipamorelin | Veldhuis JD, Keenan DM. Secretagogues govern GH secretory-burst waveform and mass in healthy eugonadal and short-term hypogonadal men. Eur J Endocrinol. 2008;159(5):547-554. PMID: 18728125. PMID 18728125 | human study |
| 2008 | Ipamorelin | Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611. PMID: 18981485. (MK-677 comparator data.) PMID 18981485 | human study |
| 2001 | Ipamorelin | Ghigo E, Arvat E, Giordano R, et al. Biologic activities of growth hormone secretagogues in humans. Endocrine. 2001;14(1):87-93. PMID: 11322506. PMID 11322506 | human study |
| 1999 | Ipamorelin | Gobburu JVS, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. PMID: 10496658. PMID 10496658 | human study |
| 2012 | Ipamorelin | Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012;4:149-155. PMID: 27186126. PMID 27186126 | preclinical, in vivo |
| 2000 | Ipamorelin | Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-577. PMID: 10828840. PMID 10828840 | preclinical, in vivo |
| 2020 | Ipamorelin | Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37. doi: 10.1002/rco2.9. | mechanism / discovery |
| 1998 | Ipamorelin | Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822. (The foundational discovery paper; establishes the selectivity claim.) PMID 9849822 | mechanism / discovery |
| 2026 | Ipamorelin | World Anti-Doping Agency. The 2026 Prohibited List. Section S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org. | regulatory / registry |
| 2025 | Ipamorelin | U.S. Food and Drug Administration. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025. | regulatory / registry |
| 2022 | Kisspeptin | Thurston L, Hunjan T, Ertl N, Wall MB, Mills EG, Suladze S, et al. Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2022;5(10):e2236131. PMID: 36227594. PMID 36227594 | human trial |
| 2018 | Kisspeptin | Trevisan CM, Montagna E, de Oliveira R, Christofolini DM, Barbosa CP, Crandall KA, Bianco B. Kisspeptin/GPR54 System: What Do We Know About Its Role in Human Reproduction? Cell Physiol Biochem. 2018;49(4):1259-1276. PMID: 30205368. PMID 30205368 | human study |
| 2017 | Kisspeptin | Comninos AN, Wall MB, Demetriou L, Shah AJ, Clarke SA, Narayanaswamy S, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017;127(2):709-719. PMID: 28112678. PMID 28112678 | human study |
| 2014 | Kisspeptin | Skorupskaite K, George JT, Anderson RA. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update. 2014;20(4):485-500. PMID: 24615662. PMID 24615662 | human study |
| 2011 | Kisspeptin | Chan YM, Butler JP, Pinnell NE, Pralong FP, Crowley WF Jr, Ren C, et al. Kisspeptin resets the hypothalamic GnRH clock in men. J Clin Endocrinol Metab. 2011;96(6):E908-915. PMID: 21470993. PMID 21470993 | human study |
| 2009 | Kisspeptin | Jayasena CN, Nijher GM, Chaudhri OB, Murphy KG, Ranger A, Lim A, et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009;94(11):… PMID 19820030 | human study |
| 2005 | Kisspeptin | Dhillo WS, Chaudhri OB, Patterson M, Thompson EL, Murphy KG, Badman MK, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005;90(12):6609-6615. PMID: 16174713. PMID 16174713 | human study |
| 2007 | Kisspeptin | Lapatto R, Pallais JC, Zhang D, Chan YM, Mahan A, Cerrato F, et al. Kiss1−/− mice exhibit more variable hypogonadism than Gpr54−/− mice. Endocrinology. 2007;148(10):4927-4936. PMID: 17595229. PMID 17595229 | preclinical, in vivo |
| 2015 | Kisspeptin | Abbara A, Jayasena CN, Christopoulos G, Narayanaswamy S, Izzi-Engbeaya C, Nijher GM, et al. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. J Clin Endocrinol Met… PMID 26192876 | preclinical, in vitro |
| 2014 | Kisspeptin | Jayasena CN, Abbara A, Comninos AN, Nijher GM, Christopoulos G, Narayanaswamy S, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124(8):3667-3677. PMID: 25036713. PMID 25036713 | preclinical, in vitro |
| 2020 | Kisspeptin | Abbara A, Eng PC, Phylactou M, Clarke SA, Hunjan T, Roberts R, et al. Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders. J Clin Invest. 2020;130(12):6739-6753. PMID: 33196464. PMID 33196464 | research article |
| 2015 | Kisspeptin | Clarke H, Dhillo WS, Jayasena CN. Comprehensive Review on Kisspeptin and Its Role in Reproductive Disorders. Endocrinol Metab (Seoul). 2015;30(2):124-141. PMID: 26194072. PMID 26194072 | research article |
Related pair pages
More research context
Frequently asked
Have Ipamorelin and Kisspeptin been studied together?
Researchers have published mechanistic-level co-administration discussion of Ipamorelin and Kisspeptin. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Ipamorelin and Kisspeptin share?
Ipamorelin and Kisspeptin do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Ipamorelin and Kisspeptin?
Ipamorelin: Not approved. Kisspeptin: Not approved; active Phase 2. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Ipamorelin and Kisspeptin?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Ipamorelin profile and the Kisspeptin profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026